Michael Ackermann, PhD

Director, Biotech, Stanford Biodesign

Michael Ackermann is Director of Biotechnology for Stanford Biodesign and an Adjunct Professor of Bioengineering at Stanford University. Michael is CEO of Osanni Bio, Inc., and is also co-founder, former CEO, and serves on the board of Presidio Medical. He was previously co-founder and Chairman of the Board of Tarsus Pharmaceuticals (NASDAQ: TARS), and was co-founder and served as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST, acquired by Viatris). Prior to this, he was Vice President, Neurostimulation for Allergan (an AbbVie company), after serving as co-founder and CEO of Oculeve, Inc., which was acquired by Allergan, plc. Michael received a BE degree from Vanderbilt University and MS and PhD degrees from Case Western Reserve University. He was a 2010-11 Innovation Fellow at Stanford Biodesign and is also an alumnus of the Stanford University Vision Research Fellowship. He has more than 50 issued US patents.

Speakers